Litcius/Paper detail

Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives

Yang Long, Guangchao Zang, Jingwen Li, Xinyue Li, Yuanzhu Li, Yinping Zhao

2020Regenerative Biomaterials55 citationsDOIOpen Access PDF

Abstract

Atherosclerosis is a key mechanism underlying the pathogenesis of cardiovascular disease, which is associated with high morbidity and mortality. In the field of precision medicine for the treatment of atherosclerosis, nanoparticle (NP)-mediated drug delivery systems have great potential, owing to their ability to release treatment locally. Cell-derived biomimetic NPs have attracted extensive attention at present due to their excellent targeting to atherosclerotic inflammatory sites, low immunogenicity and long blood circulation time. Here, we review the utility of cell-derived biomimetic NPs, including whole cells, cell membranes and extracellular vesicles, in the treatment of atherosclerosis.

Topics & Concepts

Drug deliveryCellTargeted drug deliveryDrugExtracellular vesiclesPathogenesisNanotechnologyImmunogenicityCell membraneMedicinePharmacologyChemistryCell biologyImmune systemMaterials scienceImmunologyBiologyBiochemistryExtracellular vesicles in diseaseAtherosclerosis and Cardiovascular DiseasesPhagocytosis and Immune Regulation
Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives | Litcius